Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research

“Comparative Effectiveness Research (CER) measures the effects of different drugs or other treatments on a population, with the goal of finding out which ones produce the greatest benefits for the most patients… The 2009 federal stimulus law allocated $1 billion for CER programs, and the 2010 health-care overhaul created an institute to promote CER and disseminate the results of this research to doctors and payers… Our results suggest that CER will not fulfill its promise unless it is implemented differently by researchers and understood differently by policymakers. Simply put, seeking the treatment that is most effective on average will not improve health or save money.”